Florian van Bömmel

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    Florian van Bömmel
    Medizinische Klinik m S Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Hepatology 51:73-80. 2010
  2. ncbi Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin, Campus Virchow, Berlin, Germany
    Hepatology 40:1421-5. 2004
  3. ncbi Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Hepatology 44:318-25. 2006

Detail Information

Publications3

  1. ncbi Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    Florian van Bömmel
    Medizinische Klinik m S Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Hepatology 51:73-80. 2010
    ..CONCLUSION: TDF monotherapy induced a potent and long-lasting antiviral response in NA-experienced patients with previous treatment failure. Our data may have implications for current add-on strategies...
  2. ncbi Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite, Universitatsmedizin Berlin, Campus Virchow, Berlin, Germany
    Hepatology 40:1421-5. 2004
    ..In conclusion, tenofovir may become an effective alternative for the treatment of patients with lamivudine-resistant HBV infection...
  3. ncbi Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
    Florian van Bömmel
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Hepatology 44:318-25. 2006
    ..No side effects were reported. In conclusion, these preliminary observations strongly suggest that TDF might be a highly effective rescue drug for HBV-infected patients with altered responsiveness to treatment with lamivudine and ADV...